# A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.

Source: https://onco.cc/trials/nct07283367/  
OnCo record `nct07283367` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Bevacizumab, Oxaliplatin and Capecitabine in colorectal cancer, run by Hansoh BioMedical R&D Company, now recruiting.

## Summary

A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. is a phase 1/2 interventional study registered as NCT07283367 by Hansoh BioMedical R&D Company, with 502 participants planned, started 2025-12-22 and due to reach its primary completion in 2029-12-31. Interventions recorded: Cohort 1: HS-20110+ Bevacizumab+5-FU/leucovorin, Cohort 2: HS-20110+Bevacizumab+Oxaliplatin+5-FU/leucovorin and Cohort 3: HS-20110+Bevacizumab+Oxaliplatin+Capecitabine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07283367
- Phase: 1/2
- Setting: A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-20110 Combination Therapies in Patients With Advanced Colorectal Cancer.
- Sponsor: Hansoh BioMedical R&D Company
- Enrolled: 502

## Sources

- ClinicalTrials.gov NCT07283367: https://clinicaltrials.gov/study/NCT07283367

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/)

---
JSON: https://onco.cc/api/v1/entities/nct07283367.json